The Efficacy and Safety of Afatinib in Non-Small Cell Lung Cancer Patients with Brain Metastasis: A Meta-Analysis

Table 1

Main characteristics of each study included.

First author	Year	Study design	Included studies	Treatment status	Number of BM	Age (years)/population	Pre-treatment	Dose (mg)	Quality score
Schuler [9]	2016	Coh	Lux-lung 3 adenocarcinoma	First-line	42	62/Asian	WBRT	40	6
		Coh	Lux-lung 6 adenocarcinoma	First-line	49	54/Asian	WBRT	40	6
Li [6]	2018	Coh	Adenocarcinoma	First-line	28	60/Asian	NA	40	6
Su [16]	2018	Coh	NA	First-line	306	60/Asian	NA	40	6
Tan [15]	2019	Coh	Adenocarcinoma	First-line	42	62/Asian	WBRT	30	6
Wang [13]	2019	Coh	Adenocarcinoma	First-line	24	58/Asia	SRTWBRT	40	6
Chen [14]	2019	Coh	Stage III B or IV adenocarcinoma	First-line	134	65/Asian	Radiotherapy of brain metastases	40	6
Lin [17]	2019	Coh	Adenocarcinoma	First-line	125	60/Asian	NA	40	6
Wei [18]	2019	Coh	Advanced lung adenocarcinoma	First-line	74	60/Asian	NA	40	6
Jung [12]	2020	Coh	Adenocarcinoma	First-line	157	60/Asian	SRTWBRT	40	6